Cancer Biotherapy and Radiopharmaceuticals最新文献

{"title":"Clinical Efficacy of Capecitabine and Docetaxel Efficacy in Advanced Triple-Negative Breast Cancer Along with Ultrasound-Mediated Drug Delivery.","authors":"Dongbo Liu, Yujing Liu, Zhangyu Wang, Jian Chang, Guoqiang Zhang","doi":"10.1177/10849785261420926","DOIUrl":"10.1177/10849785261420926","url":null,"abstract":"<p><strong>Objective: </strong>To assess the clinical impact of docetaxel and capecitabine administered under ultrasound-mediated enhancement in patients with advanced triple-negative breast cancer (TNBC), with an emphasis on safety, quality of life, immunological modulation, and therapeutic efficacy.</p><p><strong>Methods: </strong>A total of 80 patients with advanced TNBC who received treatment at this institution between October 2021 and October 2022 were chosen at random and placed in either the control group (CG, <i>n</i> = 40) or the observation group (OG, <i>n</i> = 40). While the OG received capecitabine and docetaxel supplemented by an ultrasound-mediated drug delivery strategy intended to enhance intratumoral absorption, the CG received cisplatin and docetaxel. The groups were compared in terms of clinical response, immunological function, quality of life (FACT-B), incidence of adverse events, and serum tumor markers.</p><p><strong>Results: </strong>Compared with the CG, the OG showed a considerably greater response rate (RR) and disease control rate (<i>p</i> < 0.05). Immunoglobulin (Ig)G, IgM, and IgA levels in the CG dramatically decreased after two treatment cycles (<i>p</i> < 0.05), while levels in the OG were maintained and continued to be greater than those in the CG (<i>p</i> < 0.05). Both groups' FACT-B scores dropped (<i>p</i> < 0.05), but the OG's reduction was less noticeable (<i>p</i> < 0.05), suggesting that ultrasound-enhanced therapy improved quality-of-life preservation. The OG had decreased incidence of adverse events; however, this difference was not statistically significant (<i>p</i> > 0.05). Following therapy, tumor markers CA125 and CA153 reduced in both cohorts (<i>p</i> < 0.05), with the OG showing larger reductions (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Capecitabine and docetaxel administered via ultrasound improve therapeutic efficacy in advanced TNBC, lessen immune suppression brought on by treatment, improve quality of life, and support a positive safety profile while encouraging higher decreases in tumor marker expression. These results demonstrate the potential therapeutic benefit of using ultrasound-based medication delivery techniques into TNBC systemic therapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"559-564"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146127731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-Enhanced Delivery of Salvianolic Acid F Targets CXCL5 to Suppress Lung Cancer Progression: Insights from <i>In Vitro</i> PC9 and H1299 Models.","authors":"Chunxia Ding, Ning Tang, Quancheng Zhou, Xianghua Wu, Miaomiao Han","doi":"10.1177/10849785251367313","DOIUrl":"10.1177/10849785251367313","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for more effective and targeted therapeutic strategies. Traditional Chinese Medicine (TCM), known for its favorable safety profile and broad pharmacological effects, offers promising candidates for cancer treatment. Salvianolic acid F (SAF), a key bioactive compound derived from <i>Salvia miltiorrhiza</i>, has demonstrated antitumor potential, but its role and underlying mechanisms in lung cancer remain inadequately characterized.</p><p><strong>Objective: </strong>This study investigated the anticancer efficacy of SAF in lung cancer and determines whether ultrasound can enhance its therapeutic effects, with a particular focus on the CXCL5/Wnt/β-catenin signaling axis.</p><p><strong>Methods: </strong>Human non-small cell lung cancer cell lines H1299 and PC9 were treated with SAF alone or in combination with ultrasound. Cell proliferation, migration, and invasion were assessed using cell counting kit-8, scratch wound healing, and transwell assays, respectively. Gene expression changes were analyzed using RNA sequencing and validated by quantitative real-time polymerase chain reaction and Western blotting. Functional involvement of CXCL5 was further confirmed through small interfering RNA-mediated gene silencing.</p><p><strong>Results: </strong>SAF significantly inhibited proliferation, motility, and invasiveness of both H1299 and PC9 cells. These effects were markedly enhanced when SAF was delivered in conjunction with ultrasound exposure. Transcriptomic analysis revealed downregulation of CXCL5 and suppression of downstream Wnt/β-catenin signaling mediators, including Wnt5α and β-catenin. CXCL5 knockdown mimicked the inhibitory effects of SAF and synergized with SAF treatment, confirming the involvement of the CXCL5/Wnt/β-catenin axis in the observed antitumor response.</p><p><strong>Conclusions: </strong>Ultrasound-enhanced delivery of SAF significantly impairs lung cancer cell proliferation and metastasis by targeting the CXCL5/Wnt/β-catenin pathway. This combinatorial approach represents a novel and promising biotherapeutic strategy for lung cancer that integrates TCM-derived compounds with noninvasive delivery technologies.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"565-573"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the <i>MCM10/p53/p21/CCND1</i> Axis in Colorectal Cancer: Evaluating the Therapeutic Potential of Ultrasound.","authors":"Hao Wu, Changyu Wen, Zheng Jiang","doi":"10.1177/10849785251364091","DOIUrl":"10.1177/10849785251364091","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC), the second leading cause of cancer-related deaths globally, continues to lack effective early diagnostic biomarkers and therapeutic strategies. Minichromosome maintenance protein 10 (<i>MCM10</i>), a replication initiation factor implicated as a pan-cancer marker, remains poorly characterized in CRC. Its role within the <i>p53/p21</i>/Cyclin D1 (<i>CCND1</i>) regulatory axis and its potential as a therapeutic target, particularly under ultrasound-based modulation, warrants investigation.</p><p><strong>Methods: </strong>Integrated bioinformatic analyses were conducted using public databases to evaluate <i>MCM10</i> expression and clinical significance. Clinical CRC specimens were analyzed via qPCR and immunohistochemistry to validate <i>MCM10</i> expression. Functional assays, including colony formation, cell counting kit-8 (CCK-8), Transwell migration/invasion, and flow cytometry, assessed the biological effects of <i>MCM10</i> knockdown on proliferation, apoptosis, and cell cycle. Western blotting and rescue experiments elucidated signaling pathways. A CRC mouse xenograft model was established to evaluate <i>in vivo</i> tumor growth. The therapeutic modulation of <i>MCM10</i>-related pathways using ultrasound-based interventions was preliminarily assessed.</p><p><strong>Results: </strong><i>MCM10</i> expression was significantly upregulated in cell lines and CRC tissues, and correlated with poor prognosis. Silencing <i>MCM10</i>-impaired CRC cell proliferation, invasion, migration, and induced G1/S cell cycle arrest suppressed epithelial-mesenchymal transition and increased apoptosis. Mechanistically, <i>MCM10</i> knockdown activated the <i>p53/p21</i> axis and downregulated <i>CCND1</i> expression. <i>In vivo</i>, <i>MCM10</i> inhibition suppressed xenograft tumor growth. Ultrasound exposure exhibited the potential to enhance the therapeutic effects of <i>MCM10</i> suppression by modulating the <i>MCM10/p53/p21/CCND1</i> axis.</p><p><strong>Conclusions: </strong>These findings reveal that <i>MCM10</i> promotes CRC malignancy through inhibiting the tumor-suppressive <i>p53/p21/CCND1</i> pathway. Targeting this axis, particularly through ultrasound-enhanced delivery or sensitization strategies, holds promise as a novel therapeutic approach in CRC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"624-635"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking Spondin-1 and Spondin-2 as Ultrasound-Responsive Biomarkers in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: Diagnostic and Therapeutic Perspectives.","authors":"Hai Ou, Feng Jin, Chenyang Wang, Shubin Wang, Yiwang Ye, Jianming Mo, Fen Wang","doi":"10.1177/10849785251403920","DOIUrl":"10.1177/10849785251403920","url":null,"abstract":"<p><p>The development of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) remains a huge challenge in treating EGFR-mutant non-small-cell lung cancer (NSCLC). Recent improvements in ultrasound-based cancer biotherapies have necessitated the discovery of responsive molecular targets that can improve therapeutic accuracy. This study looks at the diagnostic usefulness and functional importance of spondin-1 (SPON1) and spondin-2 (SPON2) in EGFR-mutated NSCLC, with a focus on their possible response to ultrasound-enhanced therapies. Plasma levels of SPON1 and SPON2 were considerably higher in EGFR-mutant NSCLC patients than in healthy controls. Receiver operating characteristic curve analysis demonstrated that both proteins had good sensitivity and specificity. SPON1 and SPON2 expression were linked with aggressive clinical characteristics such as tumor size (≥5 cm), advanced TNM stage (III-IV), and lymph node involvement. Importantly, both markers were significantly elevated in gefitinib-resistant, EGFR-mutant NSCLC cells. Functional investigations revealed that suppressing SPON1 and SPON2 reversed resistance by inhibiting proliferation and invasion while increasing apoptosis. In contrast, overexpression conferred resistance to gefitinib in parental cells. Given their dual roles in diagnosis and resistance, SPON1 and SPON2 are intriguing ultrasound-responsive biomarkers in EGFR-mutant NSCLC. These findings provide the groundwork for future incorporation of ultrasound-mediated delivery methods or sonodynamic treatments targeting SPON1/SPON2, opening up new possibilities for overcoming EGFR-TKI resistance and improving therapeutic effectiveness in resistant NSCLC.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"595-605"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cavitation-Free Acoustic Sensitization Enhances PLK4-Targeted Therapy Using the Phillyrin Derivative DE02 in Osteosarcoma.","authors":"Jin Yang, Haoyu Wang, Zongyun He, Wei Wang, Jun Qian","doi":"10.1177/10849785261446291","DOIUrl":"10.1177/10849785261446291","url":null,"abstract":"<p><strong>Objective: </strong>To ascertain whether cavitation-free acoustic sensitization enhances intracellular delivery and amplifies polo-like kinase 4 (<i>PLK4</i>)-targeted signaling to boost the phillyrin derivative DE02's antitumor efficacy against osteosarcoma, providing a secure and effective ultrasound-enabled method for targeted cancer biotherapy.</p><p><strong>Methods: </strong>Using ultracentrifugation, exosomes generated from human umbilical vein endothelial cells were separated, purified, and identified using common morphological and molecular markers. Low-energy sonication under cavitation-free acoustic circumstances was used to insert DE02 into exosomes, creating an exosomal delivery (ExoDE02) system intended to improve cellular absorption without causing membrane damage. MG-63 and Saos-2 human osteosarcoma cell lines were used as <i>in vitro</i> models. The cell counting kit-8 test was used to measure cell proliferation, proliferating cell nuclear antigen (<i>PCNA</i>) immunofluorescence was used to measure proliferative activity, and Transwell assays were used to measure migration and invasion. Enzyme-linked immunosorbent assay (ELISA), real-time quantitative PCR, and Western blotting were used to assess the expression of <i>PLK4</i> and downstream tumor protein 53 <i>(p53)</i>-cyclin-dependent kinase inhibitor 1A <i>(p21)</i> signaling components. To verify pathway specificity, <i>PLK4</i> overexpression studies were carried out. A nude mouse xenograft model was used to evaluate <i>in vivo</i> antitumor effectiveness and biosafety.</p><p><strong>Results: </strong>In a concentration-dependent manner, DE02 showed almost 10 times more antiproliferative action against osteosarcoma cells than the parent chemical phillyrin. The inhibitory effects of DE02 on osteosarcoma cell proliferation, migration, and invasion were greatly enhanced by cavitation-free acoustic sensitization-mediated ExoDE02. This was accompanied by a significant downregulation of <i>PCNA</i> and <i>PLK4</i> expression and activation of the <i>p53-p21</i> tumor suppressor pathway. The anticancer effects of DE02 and ExoDE02 were successfully inhibited by overexpression of <i>PLK4</i>, indicating <i>PLK4</i>-dependent therapeutic efficacy. ExoDE02 significantly inhibited the growth of xenograft tumors <i>in vivo</i>, decreased tumor weight and volume, and showed no discernible systemic toxicity.</p><p><strong>Conclusions: </strong>By increasing the therapeutic efficacy of the phillyrin derivative DE02 via a safe, nondestructive exosome-based delivery method, cavitation-free acoustic sensitization improves <i>PLK4</i>-targeted osteosarcoma therapy. For targeted osteosarcoma biotherapy, this ultrasound-enabled method provides a mechanistically defined and physiologically applicable platform.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"583-594"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactylation Signatures as Predictors of Prognosis and Therapeutic Response in Lung Adenocarcinoma: Implications for Ultrasound-Based Therapeutic Strategies.","authors":"Qingchun Cai, Chenglu Huang, Yu Huang, Shi Bu, Zhiqiang Wang","doi":"10.1177/10849785251407489","DOIUrl":"https://doi.org/10.1177/10849785251407489","url":null,"abstract":"<p><strong>Background: </strong>Lactylation, a unique post-translational alteration, has been identified as an important epigenetic regulator of cancer metabolism, immune evasion, and treatment resistance. Recent research reveals that ultrasound-based biophysical stimulation may change tumor microenvironmental variables that affect lactate metabolism and subsequent lactylation processes. The purpose of this study was to better understand the predictive significance of lactylation-associated genes in lung adenocarcinoma (LUAD) and how they could interact with ultrasound-mediated treatment response.</p><p><strong>Methods: </strong>Transcriptomic data from 867 LUAD samples were used to identify lactylation-related genes. Consensus clustering was used to separate LUAD cases into various lactylation subtypes. Differentially expressed genes were assessed for functional enrichment, mutation load, and immunological infiltration. A prognostic risk model was created using multivariate Cox regression analysis.</p><p><strong>Results: </strong>Nineteen major lactylation-related genes divided patients with LUAD into three molecular subgroups with different clinical outcomes. A 10-gene prognostic model accurately predicted overall survival and was associated with stronger tumor stemness, increased mutational frequency, and decreased immunotherapy effectiveness in high-risk patients. Notably, computational predictions suggested that metabolic regulation might slow lactylation-driven tumor development, implying a synergistic treatment window.</p><p><strong>Conclusion: </strong>Lactylation-associated gene profiles may serve as prognostic biomarkers and therapeutic modulators in LUAD. The combination of ultrasound-based therapies targeting lactylation pathways could be a viable technique for improving precision oncology and overcoming resistance mechanisms in lung cancer therapy.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":"41 7","pages":"606-623"},"PeriodicalIF":1.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148655047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic Evaluation of Fibroblast Activation Protein-Targeted Radiopharmaceutical Uptake in Low-Stage Rectal Cancer Tumor Microenvironment.","authors":"XuDong Zhang, Ke Duan, YuHan Long, Tong Zhou","doi":"10.1177/10849785261479557","DOIUrl":"https://doi.org/10.1177/10849785261479557","url":null,"abstract":"<p><p><i>Purpose:</i> Radionuclide therapy targeting fibroblast activation protein (FAP) offers an effective treatment for tumors with high FAP expression, such as those imaged with ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI) and treated with ¹⁷⁷Lu-FAPI. Personalized therapy planning, based on imaging-derived standardized uptake values, pharmacokinetic parameters, and dosimetric modeling, is essential to optimize therapeutic outcomes while minimizing toxicity to healthy tissues.<i>Methods and Results:</i> The study develops a comprehensive personalized therapy planning framework integrating ⁶⁸Ga-FAPI positron emission tomography (PET), pharmacokinetic modeling, and voxel-based dosimetry for optimized tumor doses and safety in ¹⁷⁷Lu-FAPI radionuclide therapy. A cohort of 26 patients (mean age: 56.3 ± 9.2 years) with stage I-II rectal cancer underwent ⁶⁸Ga-FAPI PET/computed tomography imaging after intravenous injection of ⁶⁸Ga-FAPI (150-250 MBq). SUV_max ranged from 8.5 to 12.5, with imaging performed at multiple time points (10, 30, 60, and 120 min) to capture tracer kinetics. Pharmacokinetic modeling was used to estimate uptake rate (K₁ = 0.182 ± 0.036 min^-1), washout rate (k₂ = 0.094 ± 0.021 min^-1), and retention coefficient (k₃ = 0.138 ± 0.028 min^-1).<i>Results:</i> Voxel-based dosimetry derived absorbed doses using time-activity curves and radionuclide-specific S-values. Activity scaling was applied to estimate tumor doses with 3-7 GBq of ¹⁷⁷Lu-FAPI. With 5-7 GBq of ¹⁷⁷Lu-FAPI, 92.3% of patients received tumor doses of at least 20 Gy, ranging from 18.2 to 26.4 Gy. Kidney dosages ranged from 2.2 to 5.0 Gy, whereas liver doses varied from 1.7 to 4.1 Gy. SUV_max showed a high correlation with absorbed dose (<i>r</i> = 0.88, <i>p</i> < 0.001).<i>Conclusions:</i> The methodology successfully enhanced tumor dose coverage while ensuring organ safety through activity optimization. This system offers a clinically applicable approach to targeted radionuclide therapy by combining PET imaging, pharmacokinetics, and dosimetry to deliver optimal tumor doses while meeting organ-at-risk constraints.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"10849785261479557"},"PeriodicalIF":1.7,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiopharmaceutical Oncology Care Supported by Ultrasound-Guided Superior Vena Cava-Right Atrial Junction Port Tip Positioning in Adult Cancer Patients.","authors":"Quan Ling, Yinqi Yang, Junlin Wen, Jin Liu, Yong Chen","doi":"10.1177/10849785261442223","DOIUrl":"10.1177/10849785261442223","url":null,"abstract":"<p><p><i>Background:</i> In this single-center retrospective study, the authors evaluated whether real-time ultrasound-guided positioning of an implantable venous access port catheter tip at the superior vena cava-right atrial junction (SVC-RAJ) reduces the risk of catheter-related thrombosis (CRT) in adult patients with cancer and developed a multivariable risk prediction model to support individualized prevention.<i>Methods:</i> Clinical data from 600 consecutive patients who underwent port implantation at Zhongshan People's Hospital were analyzed. Patients were grouped according to final catheter tip position (SVC-RAJ versus non-SVC-RAJ), and CRT incidence was compared between groups.<i>Results:</i> The overall incidence of CRT was 30.33% (182/600) and was significantly lower in the SVC-RAJ group than in the non-SVC-RAJ group (22.42% vs. 38.73%, <i>p</i> < 0.001). In multivariable analysis, catheter tip positioning at the SVC-RAJ remained an independent protective factor (odds ratio = 0.517, 95% confidence interval [CI]: 0.353-0.756). Age, body mass index (BMI), tumor stage, neutrophil-to-lymphocyte ratio, D-dimer level, catheterization duration, and prophylactic anticoagulation status were also independently associated with CRT. A nomogram integrating these variables demonstrated good discrimination (area under the curve = 0.866, 95% CI: 0.837-0.895), with a sensitivity of 70.33% and a specificity of 85.89%. Performance across specific age or BMI strata was not separately evaluated in this study, and further stratified validation in larger datasets is needed to assess model consistency across demographic subgroups.<i>Conclusions:</i> These findings support ultrasound-guided SVC-RAJ positioning as a clinically relevant strategy for reducing CRT risk and maintaining reliable venous access in contemporary oncology care pathways.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"459-468"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Nurse-Coordinated Care on Outcomes of Ultrasound-Assisted Radiopharmaceutical Cancer Therapy.","authors":"Yingxiu Wang","doi":"10.1177/10849785261432583","DOIUrl":"10.1177/10849785261432583","url":null,"abstract":"<p><p>Ultrasound-assisted radiopharmaceutical therapy (U-RPT) represents an emerging frontier in noninvasive cancer treatment, combining targeted radionuclide delivery with focused acoustic energy to enhance intratumoral drug uptake and therapeutic precision. Despite promising preclinical and translational outcomes, clinical implementation remains limited by procedural risks and variability in patient monitoring. In this prospective study involving 80 patients with solid tumors, we evaluated a structured nurse-coordinated care model during U-RPT to improve safety and procedural efficiency. The protocol incorporated predefined checkpoints for real-time physiological monitoring and adaptive intervention during sonication. Compared with standard care, nurse coordination resulted in significantly greater hemodynamic stability (<i>p</i> < 0.05), a 2-h reduction in recovery time (<i>p</i> < 0.01), and higher patient satisfaction scores (<i>p</i> < 0.001), while reducing the frequency of moderate and severe adverse events (<i>p</i> < 0.01). Predictive modeling identified heart rate variability and oxygen desaturation as key predictors of clinical risk (AUC = 0.74). These findings establish nurse-coordinated oversight as a critical adjunct to ultrasound-based radiopharmaceutical therapy, reinforcing the clinical safety, translational feasibility, and patient-centered potential of next-generation ultrasound oncology trials.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"450-458"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147470365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Time Super-Resolution Ultrasound Imaging for Monitoring Tumor Response During Intensive Care Management of Oncologic Emergencies.","authors":"Jinping Wu, Wentao Xu, Li Li, Wenqing Xie, Bei Tang","doi":"10.1177/10849785251376112","DOIUrl":"10.1177/10849785251376112","url":null,"abstract":"<p><strong>Background: </strong>Oncologic emergencies in critically ill cancer patients frequently require rapid, real-time assessment of tumor responses to therapeutic interventions. However, conventional imaging modalities such as computed tomography and magnetic resonance imaging are often impractical in intensive care units (ICUs) due to logistical constraints and patient instability. Super-resolution ultrasound (SR-US) imaging has emerged as a promising noninvasive alternative, facilitating bedside evaluation of tumor microvascular dynamics with exceptional spatial resolution. This study assessed the clinical utility of real-time SR-US imaging in monitoring tumor perfusion changes during emergency management in oncological ICU settings.</p><p><strong>Methods: </strong>In this prospective observational study, critically ill patients with oncologic emergencies underwent bedside SR-US imaging before and after the initiation of emergency therapy (e.g., corticosteroids, decompression, or chemotherapy). SR-US was employed to quantify microvascular parameters, including perfusion density and flow heterogeneity. Data processing incorporated artificial intelligence for real-time vessel segmentation and quantitative analysis.</p><p><strong>Results: </strong>SR-US imaging successfully detected perfusion changes within hours of therapy initiation. A significant correlation was observed between reduced tumor perfusion and clinical improvement, including symptom relief and shorter ICU stay. This technology enables visualization of microvessels as small as 30 µm, surpassing conventional ultrasound limits. No adverse events were reported with the use of contrast microbubbles. In addition, SR-US imaging reduces the need for transportation to radiology departments, thereby optimizing ICU workflow.</p><p><strong>Conclusions: </strong>Real-time SR-US imaging offers a novel, bedside-compatible method for evaluating tumor vascular response during the acute phase of oncological emergencies. Its integration into ICU care pathways could enhance timely decision-making, reduce reliance on static imaging, and support personalized cancer management. Further multicenter validation is required.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"443-449"},"PeriodicalIF":1.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}